Product news

Share this article:
The FDA has approved GlaxoSmithKline's Rotarix (rotavirus vaccine, live, oral) for the prevention of rotavirus gastroenteritis in infants. Rotarix is indicated to offer protection against the most commonly circulating rotavirus types in the US and allow infants to complete the vaccination series by four months of age. The US Centers for Disease Control and Prevention currently recommends that children complete the rotavirus immunization series by six months of age. 
 
Abbott said it has received marketing authorization from the European Commission for a new, lower-strength tablet formulation of HIV protease inhibitor, Kaletra (lopinavir/ritonavir).
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Researchers hit links for charity

The PMR Charities Golf Classic teed up more than $20,000 for St. Jude Children's Research Hospital.

FDA to review Neupogen biosimilar

Novartis subsidiary Sandoz announced Thursday that the FDA has agreed to review its filgrastim biosimilar which is already approved in 40 countries.

FDA approves a new painkiller

Targiniq ER combines the prescription opioid oxycodone and naloxone, which is often used to treat overdoses.